Subscribe
Regulatory
3 min read

Vetoquinol wins FDA approval for Felpreva, a quarterly cat treatment

Vetoquinol won FDA approval for Felpreva, a prescription topical parasiticide for cats applied four times a year, with vets able to order in 2027.

Published on
November 17, 2026
Vetoquinol wins FDA approval for Felpreva, a quarterly cat treatment

Vetoquinol has won FDA approval for Felpreva, a prescription topical parasiticide for cats that is applied just four times a year. The French animal health company describes it as a broad-spectrum treatment built for cats alone, and it has sold the product in the European Union since 2022.

Veterinarians in the U.S. will be able to order Felpreva in 2027, according to the Vetoquinol USA product page. The next scheduled update from the company is its 2026 annual sales release on January 14th, 2027.

Felpreva asks for four doses a year

The U.S. label covers fleas, ticks, mites, roundworms and tapeworms, which puts Felpreva in the same broad-spectrum lane as the monthly cat products it will sit beside on a clinic shelf.

Felpreva treats and prevents fleas for 12 weeks, and it is applied as a topical dose.

It also treats and controls black-legged ticks for 12 weeks. Lone star ticks are covered for 8 weeks, and the label applies to cats 6 months and older that weigh at least 2.2 lb.

"We are excited to bring Felpreva to U.S. veterinarians and cat owners," said Matthieu Frechin, Chairman and CEO of Vetoquinol. "Felpreva takes the complexity out of parasite control for both veterinarians and cat owners by providing a straightforward solution: fewer applications with broad-spectrum treatment and control."

The U.S. label names emodepside, praziquantel and tigolaner as the active ingredients.

Vetoquinol, founded in 1933 and based in Lure, France, has been listed on Euronext Paris since 2006 and employed 2,526 people as of June 30th, 2026, selling medicines for cattle, pigs, dogs and cats across Europe, the Americas and Asia/Pacific.

Rivals dose monthly or every two months

Felpreva enters a feline parasiticide shelf where the big names are dosed more often. Merck's Bravecto Plus for cats combines fluralaner and moxidectin and protects against fleas, ticks and heartworms for 2 months. Zoetis sells Revolution Plus for cats, a monthly selamectin and sarolaner product for cats 8 weeks and older that weigh 2.8 lb or more.

Boehringer Ingelheim's NexGard COMBO for cats is also monthly. It pairs esafoxolaner, eprinomectin and praziquantel, and it is labeled for kittens 8 weeks and older that weigh at least 1.8 lb.

Counted on label intervals, Felpreva needs one-third of the applications a monthly product does. That is 4 a year, against 6 for Bravecto Plus and 12 for the others. On the labels, all three rivals list heartworm prevention, while Felpreva's U.S. page lists fleas, ticks, mites, roundworms and tapeworms.

Cat clinic visits grew while overall visits fell

CATalyst Council data covered in our report on cat vet visits showed cat clinic visits up 2.7% year over year in the third quarter. Overall U.S. clinical visits fell 1.9% in the same period, which makes the cat gain stand out against the wider slide.

Only about 33% of household cats visit a traditional practice each year, says CATalyst Council.

Zoetis, which sells Revolution Plus, said in its third-quarter results that companion animal revenue fell 5% and dogs and cats fell 6%.

Felpreva is a prescription-only product for cats exclusively, in the U.S. as in Europe. Vetoquinol USA says veterinarians can order it in 2027.

Every Felpreva sale runs through a veterinarian.

Source: Vetoquinol via Business Wire

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
CompanAIn names animal health veteran Brük Herbst COO
People
4 min read

CompanAIn names animal health veteran Brük Herbst COO

CompanAIn, a Charleston company building an AI-native health platform for dogs, cats and horses, named Brük Herbst chief operating officer. Herbst, a former IDEXX, Covetrus and Zomedica executive, will lead its move from platform validation to commercial scale.

Read article
Read article
Pivotal Group buys animal health manufacturer Precision Science
Funding & M&A
3 min read

Pivotal Group buys animal health manufacturer Precision Science

Pivotal Group, a Phoenix investment firm, has acquired Precision Science, a Phoenix animal health contract manufacturer founded in 1989. Pivotal said a 130,000-square-foot North Phoenix plant, two-thirds complete, will add three manufacturing lines and expand into liquids.

Read article
Read article
Loyal taps Argenta for early development of its LOY-003 dog drug
Strategy
3 min

Loyal taps Argenta for early development of its LOY-003 dog drug

Loyal has brought in animal health contract manufacturer Argenta to support early-stage development of LOY-003, its daily pill for large and giant-breed dogs.

Read article
View all articles